Lumipulse® G KL-6 (Krebs von den Lungen)
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of sialylated carbohydrate antigen, KL-6 in serum or plasma.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
You will find more resources about ILDs and the KL-6 biomarker in our dedicated microsite at www.fujirebio.com/kl-6 (opens in a new window).
Product number 233207
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Other documents
FileKL-6 Whitepaper (pdf, 378.50 kb)Extra informationGuidance document on the value of measuring KL-6 in the field of lung diseases.FileKL-6 Biomarker Information - Physician Leaflet (pdf, 3.71 mb)FileLumipulse G Lung Disease Management brochure (pdf, 151.32 kb)Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Several fully automated and CLEIA-based LUMIPULSE G1200 systems from Fujirebio are right now performing fast, high sensitivity SARS CoV-2 antigen...
Aug 26, 2020
Can KL-6 be a specific marker of alveolar damage for COVID-19 patients?
There are many reference centers across Europe that have included KL-6 as one of the biomarkers within the COVID-19 protocol to strengthen the battery...
Apr 30, 2020
From Classification to disease activity
While IPF is the classic fibrosing ILD, clinical data suggest that there is a larger group of patients with differing clinical ILD diagnoses who...
Dec 17, 2019
-
Related products
-
Product inquiry
